Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia. 

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

PYX-201 produced responses in heavily pretreated head and neck squamous cell carcinoma and other solid tumors. 

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025. 

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents 

The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC)

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

Video content above is prompted by the following:

Please comment on the multidisciplinary team approach – how is this implemented in your practice setting for clinical decision making in early-stage NSCLC?

Videos

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC 

The panel discusses reassessing for respectability after certain treatments.

Management of Borderline Resectable NSCLC

The panel discusses management of resectable early-stage non–small cell lung cancer.

Management of Resectable Early Stage NSCLC with Actionable Mutations

The panel discusses the factors that go into selecting patients for adjuvant therapy.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

The panel looks at a second patient case study.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease 

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

The panel discusses treatment considerations for consolidation durvalumab.

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

EP: 1.Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

EP: 2.Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

EP: 3.Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

EP: 4.Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

EP: 5.Management of Borderline Resectable NSCLC

EP: 6.Management of Resectable Early Stage NSCLC with Actionable Mutations

EP: 7.Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

EP: 8.Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

EP: 9.Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

EP: 10.Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Latest Conference Coverage